Ayana Pharma

About

Funding history · 1 round · — total

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Ayana Pharma's primary focus in drug development?

Ayana Pharma develops liposome-based treatments for cancer, leveraging the benefits of the FDA-approved anticancer drug Doxil.

When was Ayana Pharma founded?

Ayana Pharma was founded in June 2012.

Who co-founded Ayana Pharma and what is their background?

Ayana Pharma was co-founded by Professor Yechezkel Barenholz from the Hebrew University, who is also one of Doxil's co-inventors, and Avi Molcho.

What is the current employee count for Ayana Pharma?

Ayana Pharma currently has 31 employees.

Has Ayana Pharma completed any fundraising rounds?

Ayana Pharma has completed an undisclosed fundraising round with investors including Integra Holdings and Yechezkel Barenholz. The funding supports an abbreviated new drug application (ANDA), filing, and commercialization.

What is Ayana Pharma's product, LC101, designed to do?

Ayana Pharma's product, LC101, is a lipid-based cytotoxic agent for cancer treatment and drug delivery, based on technology from the Hebrew University.

In what geographic market does Ayana Pharma operate?

Ayana Pharma's primary geographic market is the United States.

What significant regulatory approval did Ayana Pharma receive in October 2021?

In October 2021, a generic, cancer-killing Israeli drug, likely related to Ayana Pharma's work, was approved for marketing by the FDA.

What unique research approach did Ayana Pharma explore in early 2022?

In February 2022, Ayana Pharma participated in research exploring whether zero gravity could help cure cancer, by sending a drug to space.

Sectors & technology

Tags